生物学的製剤に効果不十分な乾癬性関節炎患者に おけるウパダシチニブ: フェーズ3 無作為化対照SELECT-PsA 2試験のオープンラベル延長試験の3年結果
Clin Exp Rheumatol. 2023;41(11):2286–2297 doi: 10.55563/clinexprheumatol/8l7bbk.
Data from this open-label extension showed the efficacy of upadacitinib observed at 56 weeks was maintained through to 152 weeks in the treatment of patients with PsA. No cumulative adverse effects were observed, and no new safety signals were identified.
While there are currently a wide range of treatments for PsA available, some patients still fail to achieve their treatment targets. The SELECT-PsA 2 study showed upadacitinib 15 mg and 30 mg was significantly more effective than the placebo in the treatment of patients with PsA through to 56 weeks. The results of the SELECT-PSA 2 open-label extension study provided much needed long-term data on patients with PsA and supports the favourable safety profile of upadacitinib.
Keywords:
